177Lu (half-life 6.7 days) is the ideal radionuclide for Peptide Receptor Radionuclide Therapy, as it has a particulate emission for effecting therapy, which are used for diagnostic evaluation and dosimetry.
EndolucinBeta® is GMP certified and received EU Marketing Authorization, it is an innovative radiopharmaceutical precursor for targeted radionuclide therapies and contains the active substance 177Lu chloride as a no-carrier-added radioisotope.
The use of no-carrier-added (n. c. a.) 177Lu is excellent for the efficacy and quality of therapeutic radiopharmaceuticals.
The production route of EndolucinBeta® takes advantage of highly enriched Ytterbium-176 as starting material, thereby providing the highest specific activity and an unprecedented level of radionuclidic purity. Using 177Lu in its pure form enables the specific radioactivity to be greatly increased by up to 6-times. As a result, the superior performance creates favorable preconditions for efficient radiolabeling of biomolecules such as peptides and antibodies.